(127 days)
International Technidyne Corp. FTCA510, K913861
Not Found
No
The document describes a simple in-vitro diagnostic test tube and its use with existing analyzers. There is no mention of AI or ML in the device description, intended use, or performance studies. The performance studies focus on correlation and quality control, not on the development or validation of AI/ML algorithms.
No
This device is for in-vitro diagnostic use, specifically for monitoring anticoagulation effects. It does not directly treat or prevent a disease or condition, but rather provides information used to guide therapeutic adjustments.
Yes
The device is explicitly stated to be for "in-vitro diagnostic use only" and its intended use is to "monitor anticoagulation effects of heparin" by measuring activated clotting time, which provides information to physicians for "anticoagulation adjustments." These are all functions characteristic of a diagnostic device.
No
The device description clearly states it is a test tube containing a clotting activator, a flip-top cap, and a plastic insert with a magnet. These are physical components, not software. The device is an in-vitro diagnostic test tube used with separate hardware analyzers.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicit Statement: The "Intended Use / Indications for Use" section explicitly states: "B&D ACT test tubes are for whole blood, in-vitro diagnostic use only."
- Purpose: The device is intended to be used with whole blood outside of the body (in vitro) to provide information about a patient's physiological state (their clotting time in response to heparin). This is a core characteristic of an IVD.
- Monitoring Anticoagulation: The primary purpose is to monitor the effects of heparin, which is a diagnostic activity used to guide patient treatment.
The description clearly aligns with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The sole intended use of this product is to monitor heparin and aprotinin anticoagulation in whole blood. Typically, heparin and aprotinin therapy are commonly used during coronary bypass surgery, coronary angioplasty ands several other medical/surgical procedures.
B&D Activated Clotting Time (ACT) test tubes are intended for use in monitoring anticoagulation effects of heparin. Heparin is commonly used during coronary bypass surgery, coronary angioplasty and several other medical/surgical procedures in order to prevent thrombus formation. B&D Kaolin ACT test tubes (BD-K101) are not sensitive to provinin, and are the appropriate ACT test tubes to monitor heparin in patients treated with the moderate levels of protease inhibitor, aprotinin (up to 180 KIU/mL). B&D ACT test tubes are for whole blood, in-vitro diagnostic use only. B&D ACT test tubes are to be used with several whole blood ACT analyzers currently available, such as Hemochron® ACT analyzers Model numbers: 400, 401, 800, 801 and 8000.
Product codes (comma separated list FDA assigned to the subject device)
JBP
Device Description
Activated coagulation time (ACT) test tubes are used for monitoring heparin and aprotinin anticoagulation during coronary bypass surgery, coronary angioplasty and other medical/surgical procedures. These test tubes contain a clotting activator (either diatomaceous earth or kaolin), flip-top cap and a plastic insert that retains the magnet at the bottom of the test tube. Fresh whole blood is added to the test tube, it is mixed and placed into an instrument that is designed to display the activated clotting time (ACT) when the clotting is formed. This activated clotting time (ACT) timing indicates to physicians if the patient needs any anticoagulation adjustments.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
To establish equivalence, the diatomaceous earth activated tubes (FTCA510 and BD-101) were tested two ways. First, clotting times were compared for fresh whole blood with four different heparin concentrations, as well as a baseline. The Celite® test tubes were run on Hemochron® 8000 according to the manufacturers instructions (International Technidyne Corp.). The correlation coefficient was 0.999. Second, clotting time was tested using Hemochron Quality Control Plasma (CPL2) at Normal and Abnormal levels. All values and their averages were centered around the midrange specified for the Quality Control Plasma. The kaolin activated tubes (KACT and BD-K101) were tested similarly with different levels of heparin. The correlation coefficient was 0.999. Clotting time for the kaolin tubes using Hemochron Quality Control Plasma (CPL2) at Normal and Abnormal was also determined. All values and their averages were centered around the midrange specified for the Quality Control Plasma.
It was concluded that Hemochron FTCA510 and BD-C101 are equivalent in measuring the clotting time of fresh whole blood, fresh whole blood with different levels of heparin, and Hemochron Quality Control Plasma at Normal and Abnormal levels.
It was concluded that Hemochron KACT and BD-K101 are equivalent in measuring the clotting time of fresh whole blood, fresh whole blood with different levels of heparin, and Hemochron Quality Control Plasma at Normal and Abnormal levels.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
correlation coefficient was 0.999
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
International Technidyne Corp. FTCA510, K913861
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.7140 Activated whole blood clotting time tests.
(a)
Identification. An activated whole blood clotting time tests is a device, used to monitor heparin therapy for the treatment of venous thrombosis or pulmonary embolism by measuring the coagulation time of whole blood.(b)
Classification. Class II (performance standards).
0
1111111100
510(k) Summary
Page 1 of 2
Mav 20, 1997 Prepared:
Submitted by:
OCT - 1 1997
Hardeep Dhaliwal B&D Corp. 14 Michael Drive Metuchen, NJ 0840-2223 (908) 549-8210
Device Name
Classification Name: Activated Whole Blood Clotting Time Test Activated Whole Blood Clotting Time Test Common/Usual Name: B&D Activated Clotting Time (ACT) test tubes Proprietary Name: BD-C101 (diatomaceous earth) and BD-K101(kaolin)
Predicate Device
International Technidyne Corp. FTCA510 (diatomaceous earth) - a preamendment device, marketed since 1970, and KACT (K913861).
Device Description
Activated coagulation time (ACT) test tubes are used for monitoring heparin and aprotinin anticoagulation during coronary bypass surgery, coronary angioplasty and other medical/surgical procedures. These test tubes contain a clotting activator (either diatomaceous earth or kaolin), flip-top cap and a plastic insert that retains the magnet at the bottom of the test tube. Fresh whole blood is added to the test tube, it is mixed and placed into an instrument that is designed to display the activated clotting time (ACT) when the clotting is formed. This activated clotting time (ACT) timing indicates to physicians if the patient needs any anticoagulation adjustments.
Statement of Intended Use
The sole intended use of this product is to monitor heparin and aprotinin anticoagulation in whole blood. Typically, heparin and aprotinin therapy are commonly used during coronary bypass surgery, coronary angioplasty ands several other medical/surgical procedures.
Summary of Technological Characteristics
Both the predicate device (FTCA510) and BD-C101 contain diatomaceous earth as the activato. Composition of the test tubes are glass test tubes 13 x 100 mm, polyethylene flip-top caps and inserts, and ceramic magnets.
Both the predicate device (KACT) and BD-K101 contain kaolin as the activator. Composition of the test tubes are glass tubes 13 x 100 mm, polyethylene flip-top caps and inserts, and ceramic magnets.
1
510(k) Summary
Summary of Performance Data
To establish equivalence, the diatomaceous earth activated tubes (FTCA510 and BD-101) were tested two ways. First, clotting times were compared for fresh whole blood with four different heparin concentrations, as well as a baseline. The Celite® test tubes were run on Hemochron® 8000 according to the manufacturers instructions (International Technidyne Corp.). The correlation coefficient was 0.999.
Second, clotting time was tested using Hemochron Quality Control Plasma (CPL2) at Normal and Abnormal levels. All values and their averages were centered around the midrange specified for the Quality Control Plasma.
The kaolin activated tubes (KACT and BD-K101) were tested similarly with different levels of heparin. The correlation coefficient was 0.999.
Clotting time for the kaolin tubes using Hemochron Quality Control Plasma (CPL2) at Normal and Abnormal was also determined. All values and their averages were centered around the midrange specified for the Quality Control Plasma.
It was concluded that Hemochron FTCA510 and BD-C101 are equivalent in measuring the clotting time of fresh whole blood, fresh whole blood with different levels of heparin, and Hemochron Quality Control Plasma at Normal and Abnormal levels.
It was concluded that Hemochron KACT and BD-K101 are equivalent in measuring the clotting time of fresh whole blood, fresh whole blood with different levels of heparin, and Hemochron Quality Control Plasma at Normal and Abnormal levels.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread, forming a human figure.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Hardeep Dhaliwal President B&D Corporation 14 Michael Drive Metuchen, New Jersey 08840
OCT - 1 1997
Re : K971935 B&D Activated Clotting Time Test Tubes BD-C101 II Requlatory Class: Product Code: JBP July 17, 1997 Dated: Received: July 23, 1997
Dear Mr. Dhaliwal:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the market is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Failure to Administration (FDA) will verify such assumptions. comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations .
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Litman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure - - - -
4
510/k) Number (if known): K971935
Device Name: R&D Activated Clotting Time Test Tubes - BD-C101 (Celite) & BD-K101 (Kaoli Indications For Use:
Modify the intended use to reflect the correct function of aprotinin. Request 1.
page 6 of the submission has been modified as follows: Response:
Intended use:
B&D Activated Clotting Time (ACT) test tubes are intended for use in monitoring anticoagulation effects of heparin. Heparin is commonly used during coronary bypass surgery, coronary angioplasty and several other medical/surgical procedures in order to prevent thrombus formation. B&D Kaolin ACT test tubes (BD-K101) are not sensitive to provinin, and are the appropriate ACT test tubes to monitor heparin in patients treated with the moderate levels of protease inhibitor, aprotinin (up to 180 KIU/mL). B&D ACT test tubes are for whole blood, in-vitro diagnostic use only. B&D ACT test tubes are to be used with several whole blood ACT analyzers currently available, such as Hemochron® ACT analyzers Model numbers: 400, 401, 800, 801 and 8000.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | 97935 |
| Prescription Use (Per 21 CFR 801.109) | OR | Over-The-Counter Use |
|---|---|---|
| --------------------------------------- | ---- | ---------------------- |
(Optional Format 1-2-96)
『